Latest News
-
Mandatory Testing for Indian Spices Destined for Singapore, Hong Kong After Ban -
TRAI Advocates for Enhanced Telecom Infrastructure Sharing Among Licensees -
LTIMindtree Reports Slight Q4 Profit Dip, Optimistic About Upcoming Growth -
Axis Bank Announces Q4 Net Profit at Rs 7,599 Crore Amid Deposit Accretion Worries -
hBits Expands to Pune with CyberCity Magarpatta Acquisition, Eyes Investment Opportunities -
India's First Green Hydrogen Pilot Project Goes Live at Nathpa Jhakri -
DCB Bank Q4 Results: PAT Grew 9% To Rs 156 Cr, NII Jumps 4.5%; Dividend Declared -
RBI Halts New Customer Onboarding at Kotak Mahindra Bank Over IT Compliance -
Macrotech Developers' Annual Profit Triples Despite Q4 Dip -
DoT Engages TRAI for Equitable Satcom Spectrum Allocation Guidelines
Ranbaxy lab reports losses in its Q3 results
The company's net loss stood at Rs 307 crore corresponding quarter previous year.
It's total income increased from Rs 2,021.5 crore for the quarter ended September 30, 2010 to Rs 2,197 crore for the quarter ended September 30, 2011.
It's EBITDA stood at 11% during the quarter.
Commenting on the results, Mr Arun Sawhney, CEO and Managing Director, Ranbaxy, said, “Ranbaxy’s focus on long term improvement of its base business and margins has begun to reflect in the company’s performance. This is resulting from an increased focus on strengthening manufacturing processes while realigning our products and markets for value creation.”
The stock of Ranbaxy Lab slumped the most on the Bombay Stock Exchange after announcing the results. The stock ended low by 21.40 points or 4.31% at Rs 475.40.
GoodReturns.in
